Inhibition of PRC1 suppressed recruitment of immunoinhibitory cell types and dramatically increased the efficacy of double checkpoint immunotherapy (anti-CTLA-4 + anti-PD-1) in murine models for DNPC, indicated by the significant decline in tumor burden as well as emergence of CTLs and CD4+ effectors 88. The gene discussed is PRC1; the disease is neoplasm.